Yesterday, the phase 2 data for Cansino biologics was published in The Lancet, which is linked HERE. This phase 2 trial was looking at the COVID-19 vaccine that this company made which is an adenovirus type-5 (Ad5)-vectored COVID-19 vaccine. The trial was done in Wuhan, China on individuals who tested negative for COVID-19 in the past. It was a large trial (about 500 participants). They had 3 groups which consisted of 1 control group and 2 groups receiving a different dose of vaccine. They concluded that significant neutralizing antibodies to COVID-19 appeared in both groups of participants that received the vaccine after 14 days and were still present when tested again on day 28. There were some adverse effects. The majority were mild to moderate while a handful was severe. The severe adverse effects consisted of a fever.
CanSino and it's scientists concluded that: The Ad5-vectored COVID-19 vaccine at 5×10¹⁰ viral particles is safe, and induced significant immune responses in the majority of recipients after a single immunization.
There will be a phase 3 trial starting soon which will be a global trial.